615 Results

Mallinckrodt announces positive top-line results from its pivotal phase III CONFIRM trial of terlipressin in patients with hepatorenal syndrome Type 1.

 Added 3 days ago

Mallinckrodt Plc announced positive top-line results from its pivotal Phase III CONFIRM clinical study evaluating the efficacy and safety of...

Lynparza met the primary endpoint of significantly increasing the time prostate cancer patients selected for BRCA1/2 or ATM mutations live without radiographic disease progression.

 Added 11 days ago

AstraZeneca and MSD Inc., Kenilworth, N.J., announced positive results from the Phase III PROfound trial of Lynparza (olaparib) in men...

Phase III IMvigor130 study of Tecentriq reduces the risk of disease worsening or death in previously untreated locally advanced or metastatic urothelial carcinoma

 Added 13 days ago

Genentech, a member of the Roche Group announced that the Phase III IMvigor130 study met its co-primary endpoint of investigator-assessed...

Baxter International Inc. announces 510(k) clearance of the PrisMax system and integrated TherMax blood warmer for continuous renal replacement therapy.

 Added 18 days ago

Baxter International Inc. has announced 510(k) clearance of the PrisMax system and integrated TherMax blood warmer, the company’s next-generation platform...

FDA approves Accrufer to treat iron deficiency

 Added 23 days ago

Shield Therapeutics plc announces that the FDA has approved its lead product Feraccru / Accrufer for the treatment of iron...

New England Journal of Medicine publishes roxadustat China phase III results for the treatment of anemia in chronic kidney disease patients receiving dialysis

 Added 24 days ago

FibroGen, Inc. announced the publication of clinical study results in the New England Journal of Medicine (NEJM)1 from the China...

Roxadustat China phase III trial for treatment of anemia in chronic kidney disease patients not on dialysis published in the NEJM

 Added 24 days ago

FibroGen, Inc. announced publication of results from the Phase III trial of the efficacy and safety of roxadustat treatment compared...

FDA accepts NDA to make Procysbi available as oral granules in packets to treat nephropathic cystinosis

 Added 1 month ago

Horizon Therapeutics plc announced that the FDA has accepted Horizon’s New Drug Application (NDA) for Procysbi (Cysteamine Bitartrate) Delayed-Release Oral...

Seattle Genetics + Astellas submit a BLA to the FDA for accelerated approval for enfortumab vedotin for metastatic urothelial cancer.

 Added 1 month ago

Seattle Genetics, Inc. and Astellas Pharma Inc. announced submission of a Biologics License Application for accelerated approval to the FDA...

MDNA Life Sciences with Aspire Pharma launches the Mitomic Prostate Test to identify prostate cancer.

 Added 1 month ago

MDNA Life Sciences announces that its breakthrough Mitomic Prostate Test (MPT) – the world’s most accurate blood test to determine...

Load more